Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Ann Rheum Dis
; 79(6): 724-726, 2020 06.
Article
en En
| MEDLINE
| ID: mdl-32349982
ABSTRACT
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Esclerodermia Sistémica
/
Infecciones por Coronavirus
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article